documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
19,583 rows where agency_id = "FDA" and document_type = "Notice" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date)
These facets timed out: document_type
posted_year >30
agency_id 1
- FDA · 19,583 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2023-N-0119-0020 | FDA | FDA-2023-N-0119 | Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments | Notice | Request for Comments | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-07-11T03:59:59Z | 2026-02-27T19:57:39Z | 2026-03961 | 1 | 0 | 09000064b91e326c |
| FDA-2007-D-0369-2428 | FDA | FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T19:14:17Z | 2026-03963 | 0 | 0 | 09000064b91e3271 | |
| FDA-1991-N-0191-0010 | FDA | Civil money penalties:biologics, drugs and medical devices FDA-1991-N-0191 | Civil Money Penalties; Biologics, Drugs, and Medical Devices; Extension of Comment Period; Correction and Addition Period; Correction and Addition | Notice | Notice of Extension | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 1993-08-26T03:59:59Z | 2026-02-28T02:00:09Z | 93-17833 | 0 | 0 | 090000648052deaf |
| FDA-2026-N-1486-0001 | FDA | FDA-2026-N-1486 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZYCUBO (Copper Histidinate) | Notice | Announcement | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-02-27T20:11:11Z | 2026-03925 | 0 | 0 | 09000064b91e323b | |
| FDA-2026-N-1628-0001 | FDA | FDA-2026-N-1628 | International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Scheduling Recommendations; N-Pyrrolidino Isotonitazene; N-Desethyl Etonitazene; Coca Leaf; MDMB-FUBINACA; Request for Comments | Notice | Request for Comments | 2026-02-27T05:00:00Z | 2026 | 2 | 2026-02-27T05:00:00Z | 2026-03-06T04:59:59Z | 2026-02-27T20:18:13Z | 2026-03914 | 1 | 0 | 09000064b91e31af |
| FDA-2024-E-3572-0007 | FDA | FDA-2024-E-3572 | Determination of Regulatory Review Period for Purposes of Patent Extension; TEVIMBRA | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:52:55Z | 2026-03851 | 1 | 0 | 09000064b91deb48 |
| FDA-2025-E-0161-0006 | FDA | FDA-2025-E-0161 | Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:55:38Z | 2026-03848 | 1 | 0 | 09000064b91deb09 |
| FDA-2024-E-3565-0006 | FDA | FDA-2024-E-3565 | Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:38:14Z | 2026-03855 | 1 | 0 | 09000064b91e03ee |
| FDA-2024-E-3555-0007 | FDA | FDA-2024-E-3555 | Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:35:08Z | 2026-03855 | 1 | 0 | 09000064b91dec48 |
| FDA-2025-N-2549-0004 | FDA | FDA-2025-N-2549 | Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational Device Exemptions Reports and Records | Notice | 30 Day Proposed Information Collection | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-03-31T03:59:59Z | 2026-02-26T20:50:21Z | 2026-03857 | 1 | 0 | 09000064b91dec05 |
| FDA-2025-E-1226-0007 | FDA | FDA-2025-E-1226 | Determination of Regulatory Review Period for Purposes of Patent Extension; AEROPACE | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:32:36Z | 2026-03849 | 1 | 0 | 09000064b91dec81 |
| FDA-2025-E-1229-0006 | FDA | FDA-2025-E-1229 | Determination of Regulatory Review Period for Purposes of Patent Extension; MERIT MEDICAL WRAPSODY | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:43:12Z | 2026-03853 | 1 | 0 | 09000064b91e03f1 |
| FDA-2025-E-0371-0006 | FDA | FDA-2025-E-0371 | Determination of Regulatory Review Period for Purposes of Patent Extension; REVUFORJ | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:46:51Z | 2026-03847 | 1 | 0 | 09000064b91dec08 |
| FDA-2024-E-3564-0006 | FDA | FDA-2024-E-3564 | Determination of Regulatory Review Period for Purposes of Patent Extension; LIMFLOW SYSTEM | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:36:56Z | 2026-03855 | 1 | 0 | 09000064b91e03ed |
| FDA-2025-E-0500-0006 | FDA | FDA-2025-E-0500 | Determination of Regulatory Review Period for Purposes of Patent Extension; TRYNGOLZA | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-26T20:57:25Z | 2026-03850 | 1 | 0 | 09000064b91deac5 |
| FDA-2025-E-1228-0006 | FDA | FDA-2025-E-1228 | Determination of Regulatory Review Period for Purposes of Patent Extension; MERIT MEDICAL WRAPSODY | Notice | Determinations | 2026-02-26T05:00:00Z | 2026 | 2 | 2026-02-26T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-27T10:00:26Z | 2026-03853 | 1 | 0 | 09000064b91dec45 |
| FDA-2025-N-0195-0003 | FDA | FDA-2025-N-0195 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:43:32Z | 2026-03774 | 0 | 0 | 09000064b91da9f5 | |
| FDA-2011-N-0179-0041 | FDA | FDA-2011-N-0179 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:54:39Z | 2026-03774 | 0 | 0 | 09000064b91da06e | |
| FDA-2025-N-0339-0005 | FDA | FDA-2025-N-0339 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:48:04Z | 2026-03774 | 0 | 0 | 09000064b91da190 | |
| FDA-2010-D-0350-0035 | FDA | FDA-2010-D-0350 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Retailer Training Programs | Notice | 30 Day Proposed Information Collection | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-03-28T03:59:59Z | 2026-02-25T21:05:09Z | 2026-03771 | 1 | 0 | 09000064b91d5d25 |
| FDA-2024-N-5579-0004 | FDA | FDA-2024-N-5579 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:45:07Z | 2026-03774 | 0 | 0 | 09000064b91daa30 | |
| FDA-2025-N-0734-0004 | FDA | FDA-2025-N-0734 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:41:54Z | 2026-03774 | 0 | 0 | 09000064b91da9f4 | |
| FDA-2025-N-0418-0006 | FDA | FDA-2025-N-0418 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:49:26Z | 2026-03774 | 0 | 0 | 09000064b91da191 | |
| FDA-2026-D-1256-0001 | FDA | FDA-2026-D-1256 | Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T19:04:38Z | 2026-03713 | 0 | 0 | 09000064b91da53f | |
| FDA-2026-N-0027-0001 | FDA | FDA-2026-N-0027 | Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing | Notice | 60 Day Proposed Information Collection | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-25T19:16:33Z | 2026-03773 | 1 | 0 | 09000064b91da53a |
| FDA-2025-N-0373-0005 | FDA | FDA-2025-N-0373 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:38:37Z | 2026-03774 | 0 | 0 | 09000064b91da9f3 | |
| FDA-2025-N-0706-0004 | FDA | FDA-2025-N-0706 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:35:42Z | 2026-03774 | 0 | 0 | 09000064b91da698 | |
| FDA-2024-N-5944-0005 | FDA | FDA-2024-N-5944 | Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals | Notice | Notice of Approval | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-02-25T18:46:30Z | 2026-03774 | 0 | 0 | 09000064b91da18f | |
| FDA-2026-N-0496-0001 | FDA | FDA-2026-N-0496 | Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds | Notice | 60 Day Proposed Information Collection | 2026-02-25T05:00:00Z | 2026 | 2 | 2026-02-25T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-25T18:59:39Z | 2026-03772 | 1 | 0 | 09000064b91da591 |
| FDA-2026-N-0686-0001 | FDA | FDA-2026-N-0686 | Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements | Notice | 60 Day Proposed Information Collection | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-24T05:00:00Z | 2026-04-28T03:59:59Z | 2026-02-24T19:45:30Z | 2026-03589 | 1 | 0 | 09000064b91d5809 |
| FDA-2026-N-0008-0001 | FDA | FDA-2026-N-0008 | Advisory Committee; Gastrointestinal Drugs Advisory Committee; Renewal | Notice | Notice of Renewal | 2026-02-24T05:00:00Z | 2026 | 2 | 2026-02-24T05:00:00Z | 2026-02-24T20:00:59Z | 2026-03587 | 0 | 0 | 09000064b91d5691 | |
| FDA-2025-N-4348-0007 | FDA | FDA-2025-N-4348 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act | Notice | 30 Day Proposed Information Collection | 2026-02-23T05:00:00Z | 2026 | 2 | 2026-02-23T05:00:00Z | 2026-03-26T03:59:59Z | 2026-02-23T19:24:04Z | 2026-03448 | 1 | 0 | 09000064b91d0371 |
| FDA-2025-P-1808-0004 | FDA | FDA-2025-P-1808 | Determination That Klonopin (Clonazepam) Tablets, 0.125 Milligrams and 0.25 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-02-23T05:00:00Z | 2026 | 2 | 2026-02-23T19:17:58Z | 2026-03495 | 0 | 0 | 09000064b91d0373 | ||
| FDA-2026-N-0672-0001 | FDA | FDA-2026-N-0672 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; WASKYRA (etuvetidigene autotemcel) | Notice | Announcement | 2026-02-23T05:00:00Z | 2026 | 2 | 2026-02-23T19:28:45Z | 2026-03493 | 0 | 0 | 09000064b91d029d | ||
| FDA-2024-N-1939-0023 | FDA | FDA-2024-N-1939 | Requirements for Additional Traceability Records for Certain Foods; Exemption for Cottage Cheese Regulated by the National Conference on Interstate Milk Shipments Grade ‘‘A’’ Pasteurized Milk Ordinance | Notice | Announcement | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-02-20T19:57:25Z | 2026-03362 | 0 | 0 | 09000064b91c75b3 | |
| FDA-2026-N-0746-0001 | FDA | FDA-2026-N-0746 | Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program | Notice | 60 Day Proposed Information Collection | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-04-22T03:59:59Z | 2026-02-21T10:00:24Z | 2026-03326 | 1 | 0 | 09000064b91c75af |
| FDA-2026-N-1224-0001 | FDA | FDA-2026-N-1224 | Masuu Global Solutions LLC, U.S. Agent for Extrovis AG, et al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications | Notice | Withdrawal | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-02-20T20:33:28Z | 2026-03411 | 0 | 0 | 09000064b91c30c7 | |
| FDA-2026-N-1305-0001 | FDA | FDA-2026-N-1305 | Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drugs for Minor Use and Minor Species | Notice | 60 Day Proposed Information Collection | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-04-22T03:59:59Z | 2026-02-20T20:30:11Z | 2026-03353 | 1 | 0 | 09000064b91c750d |
| FDA-2025-D-2837-0001 | FDA | FDA-2025-D-2837 | Questions and Answers About Requirements for Additional Traceability Records for Certain Foods; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-02-20T20:36:36Z | 2026-03363 | 0 | 0 | 09000064b91c3081 | |
| FDA-2026-N-0499-0001 | FDA | FDA-2026-N-0499 | Agency Information Collection Activities; Proposed Collection; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice | Notice | 60 Day Proposed Information Collection | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-04-22T03:59:59Z | 2026-02-20T20:23:05Z | 2026-03332 | 1 | 0 | 09000064b91c75b1 |
| FDA-2026-N-0684-0001 | FDA | FDA-2026-N-0684 | Agency Information Collection Activities; Proposed Collection; Comment Request; Approved Organizations for Wholesale Drug Distributors and Third-Party Logistics Providers | Notice | 60 Day Proposed Information Collection | 2026-02-20T05:00:00Z | 2026 | 2 | 2026-02-20T05:00:00Z | 2026-04-22T03:59:59Z | 2026-02-20T20:51:55Z | 2026-03333 | 1 | 0 | 09000064b91c307f |
| FDA-2025-N-1927-0102 | FDA | FDA-2025-N-1927 | GRAS Notice (GRN) 1220 - Mycelial biomass from Pleurotus pulmonarius – amendments | Notice | General Notice | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T18:41:53Z | 0 | 0 | 09000064b91b9273 | ||
| FDA-2025-N-1928-0048 | FDA | FDA-2025-N-1928 | GRAS Notice (GRN) 1260 - Rebaudioside M - amendments | Notice | General Notice | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T18:44:51Z | 0 | 0 | 09000064b91b93bd | ||
| FDA-2025-N-1928-0051 | FDA | FDA-2025-N-1928 | GRAS Notice (GRN) 1284 - Recombinant bovine lactoferrin produced by a modified strain of Komagataella phaffii | Notice | General Notice | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T18:46:12Z | 0 | 0 | 09000064b91b93c0 | ||
| FDA-2004-N-0451-0061 | FDA | Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards FDA-2004-N-0451 | Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 065 | Notice | Announcement | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-21T03:50:57Z | 2026-03310 | 1 | 0 | 09000064b91bd3d2 | |
| FDA-2025-N-0342-0002 | FDA | FDA-2025-N-0342 | Sherri Insprucker: Final Debarment Order | Notice | Statutory Debarment | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-23T20:20:09Z | 2026-03254 | 1 | 0 | 09000064b91bd40a | |
| FDA-2025-N-1928-0050 | FDA | FDA-2025-N-1928 | GRAS Notice (GRN) 1269 - Modified-monellin preparation – amendments | Notice | General Notice | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T18:45:53Z | 0 | 0 | 09000064b91b93bf | ||
| FDA-2025-N-1927-0101 | FDA | FDA-2025-N-1927 | GRAS Notice (GRN) 1165 - (R)-1,3-Butanediol | Notice | General Notice | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T18:40:51Z | 0 | 0 | 09000064b91b93b8 | ||
| FDA-2026-N-0498-0001 | FDA | FDA-2026-N-0498 | Agency Information Collection Activities; Proposed Collection; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products | Notice | 60 Day Proposed Information Collection | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-04-21T03:59:59Z | 2026-02-19T20:20:32Z | 2026-03311 | 1 | 0 | 09000064b91bd409 |
| FDA-2025-N-0309-0002 | FDA | FDA-2025-N-0309 | Sherrie R. McCain: Final Debarment Order | Notice | Statutory Debarment | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-23T20:20:44Z | 2026-03252 | 1 | 0 | 09000064b91bd493 | |
| FDA-2026-N-1309-0001 | FDA | FDA-2026-N-1309 | Revocation of Authorization of Emergency Use of ExThera Medical Corporation Seraph 100 Microbind Affinity Blood Filter (Seraph 100); Availability | Notice | Announcement | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T20:52:19Z | 2026-03250 | 0 | 0 | 09000064b91bd344 | |
| FDA-2025-N-0345-0002 | FDA | FDA-2025-N-0345 | Justin Insprucker: Final Debarment Order | Notice | Statutory Debarment | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-21T03:49:27Z | 2026-03253 | 1 | 0 | 09000064b91bd4c5 | |
| FDA-2025-N-1928-0049 | FDA | FDA-2025-N-1928 | GRAS Notice (GRN) 1261 - 2'-Fucosyllactose - amendment | Notice | General Notice | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-02-19T18:45:13Z | 0 | 0 | 09000064b91b93be | ||
| FDA-2025-E-0862-0006 | FDA | FDA-2025-E-0862 | Determination of Regulatory Review Period for Purposes of Patent Extension; SYMVESS | Notice | Determinations | 2026-02-19T05:00:00Z | 2026 | 2 | 2026-02-19T05:00:00Z | 2026-04-21T03:59:59Z | 2026-02-19T20:54:45Z | 2026-03312 | 1 | 0 | 09000064b91bd33f |
| FDA-2025-N-1812-0002 | FDA | FDA-2025-N-1812 | Agency Information Collection Activities; Proposed Collection; Comment Request; Q-Submission and Early Payor Feedback Request Programs and Medical Device Development Tools | Notice | 30 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-03-21T03:59:59Z | 2026-02-18T18:59:05Z | 2026-03096 | 1 | 0 | 09000064b91b9022 |
| FDA-2024-N-1055-0004 | FDA | FDA-2024-N-1055 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request Data To Support Social and Behavioral Research as Used by the Food and Drug Administration | Notice | 30 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-03-21T03:59:59Z | 2026-02-18T19:28:44Z | 2026-03099 | 1 | 0 | 09000064b91b8e75 |
| FDA-2025-N-0615-0002 | FDA | FDA-2025-N-0615 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Quick Turnaround Testing of Communication Effectiveness | Notice | 30 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-03-21T03:59:59Z | 2026-02-18T18:51:59Z | 2026-03095 | 1 | 0 | 09000064b91b90b3 |
| FDA-2026-N-0497-0001 | FDA | FDA-2026-N-0497 | Agency Information Collection Activities; Proposed Collection; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions | Notice | 60 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-04-21T03:59:59Z | 2026-02-18T19:12:13Z | 2026-03094 | 1 | 0 | 09000064b91b8f13 |
| FDA-2026-N-0958-0001 | FDA | FDA-2026-N-0958 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZEVASKYN (Prademagene Zamikeracel) | Notice | Announcement | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T19:14:39Z | 2026-03211 | 0 | 0 | 09000064b91b8ec7 | ||
| FDA-2025-N-2652-0006 | FDA | FDA-2025-N-2652 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents | Notice | 30 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-03-21T03:59:59Z | 2026-02-18T19:08:22Z | 2026-03098 | 1 | 0 | 09000064b91b8fa6 |
| FDA-2025-N-1560-0002 | FDA | FDA-2025-N-1560 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Products Requirements | Notice | 30 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-03-21T03:59:59Z | 2026-02-18T19:24:09Z | 2026-03097 | 1 | 0 | 09000064b91b8ec4 |
| FDA-2025-N-0308-0003 | FDA | FDA-2025-N-0308 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Emerging Drug Safety Technology Program | Notice | 30 Day Proposed Information Collection | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T05:00:00Z | 2026-03-21T03:59:59Z | 2026-02-18T18:55:14Z | 2026-03093 | 1 | 0 | 09000064b91b9066 |
| FDA-2025-P-3575-0003 | FDA | FDA-2025-P-3575 | Determination That TOLECTIN DS (Tolmetin Sodium) Capsule, Equivalent to 400 Milligrams Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-02-18T05:00:00Z | 2026 | 2 | 2026-02-18T19:03:46Z | 2026-03213 | 0 | 0 | 09000064b91b901e | ||
| FDA-2025-E-0357-0006 | FDA | FDA-2025-E-0357 | Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:41:11Z | 2026-02971 | 1 | 0 | 09000064b91a9f20 |
| FDA-2025-E-0359-0006 | FDA | FDA-2025-E-0359 | Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:43:37Z | 2026-02971 | 1 | 0 | 09000064b91a9ff7 |
| FDA-2024-E-3532-0006 | FDA | FDA-2024-E-3532 | Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:54:42Z | 2026-02974 | 1 | 0 | 09000064b91aa73f |
| FDA-2025-E-2426-0006 | FDA | FDA-2025-E-2426 | Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-08-13T03:59:59Z | 2026-02-13T20:03:13Z | 2026-02901 | 1 | 0 | 09000064b91aa6fb |
| FDA-2024-E-3876-0006 | FDA | FDA-2024-E-3876 | Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-20T20:30:13Z | 2026-02903 | 1 | 0 | 09000064b91a8f34 |
| FDA-2025-E-0483-0006 | FDA | FDA-2025-E-0483 | Determination of Regulatory Review Period for Purposes of Patent Extension; ALYFTREK | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:46:46Z | 2026-02968 | 1 | 0 | 09000064b91aa742 |
| FDA-2025-E-0362-0006 | FDA | FDA-2025-E-0362 | Determination of Regulatory Review Period for Purposes of Patent Extension; AUCATZYL | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T20:01:58Z | 2026-02972 | 1 | 0 | 09000064b91a9ffe |
| FDA-2025-E-0370-0006 | FDA | FDA-2025-E-0370 | Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T20:10:45Z | 2026-02976 | 1 | 0 | 09000064b91a8f35 |
| FDA-2025-E-0361-0006 | FDA | FDA-2025-E-0361 | Determination of Regulatory Review Period for Purposes of Patent Extension; AUCATZYL | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T20:00:39Z | 2026-02972 | 1 | 0 | 09000064b91aa73c |
| FDA-2025-E-0360-0006 | FDA | FDA-2025-E-0360 | Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:44:45Z | 2026-02971 | 1 | 0 | 09000064b91a9ff8 |
| FDA-2024-E-3872-0006 | FDA | FDA-2024-E-3872 | Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-20T20:30:14Z | 2026-02903 | 1 | 0 | 09000064b91aa6a8 |
| FDA-2024-E-3873-0006 | FDA | FDA-2024-E-3873 | Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-20T20:30:13Z | 2026-02903 | 1 | 0 | 09000064b91a6c3d |
| FDA-2025-E-0492-0006 | FDA | FDA-2025-E-0492 | Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:36:15Z | 2026-02973 | 1 | 0 | 09000064b91a9f1c |
| FDA-2025-E-0491-0006 | FDA | FDA-2025-E-0491 | Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:34:31Z | 2026-02973 | 1 | 0 | 09000064b91aa8fb |
| FDA-2025-E-0508-0006 | FDA | FDA-2025-E-0508 | Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:37:35Z | 2026-02973 | 1 | 0 | 09000064b91a9f1e |
| FDA-2025-E-0358-0006 | FDA | FDA-2025-E-0358 | Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:42:24Z | 2026-02971 | 1 | 0 | 09000064b91a9ff6 |
| FDA-2025-E-0369-0006 | FDA | FDA-2025-E-0369 | Determination of Regulatory Review Period for Purposes of Patent Extension; KEBILIDI | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T20:09:40Z | 2026-02976 | 1 | 0 | 09000064b91a72ba |
| FDA-2023-D-2925-4518 | FDA | FDA-2023-D-2925 | Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals; Guidance for Industry; Availability | Notice | Notice of Availability | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T20:12:58Z | 2026-02934 | 0 | 0 | 09000064b91aa7ca | ||
| FDA-2024-E-3534-0006 | FDA | FDA-2024-E-3534 | Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:56:16Z | 2026-02974 | 1 | 0 | 09000064b91a9ffc |
| FDA-2025-E-0355-0006 | FDA | FDA-2025-E-0355 | Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-13T19:39:29Z | 2026-02971 | 1 | 0 | 09000064b91aa814 |
| FDA-2024-E-3875-0006 | FDA | FDA-2024-E-3875 | Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-20T20:30:13Z | 2026-02903 | 1 | 0 | 09000064b91a8f33 |
| FDA-2024-E-3874-0006 | FDA | FDA-2024-E-3874 | Determination of Regulatory Review Period for Purposes of Patent Extension; RYTELO | Notice | Determinations | 2026-02-13T05:00:00Z | 2026 | 2 | 2026-02-13T05:00:00Z | 2026-04-15T03:59:59Z | 2026-02-20T20:30:13Z | 2026-02903 | 1 | 0 | 09000064b91a8f32 |
| FDA-2025-N-0435-0002 | FDA | FDA-2025-N-0435 | Jeremy Spencer Brown: Final Debarment Order | Notice | Statutory Debarment | 2026-02-12T05:00:00Z | 2026 | 2 | 2026-02-12T05:00:00Z | 2026-02-12T18:22:54Z | 2026-02786 | 1 | 0 | 09000064b91a64fb | |
| FDA-2012-D-1197-0013 | FDA | FDA-2012-D-1197 | Certification Process for Designated Medical Gases; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request | Notice | Notice of Availability | 2026-02-12T05:00:00Z | 2026 | 2 | 2026-02-12T05:00:00Z | 2026-02-12T18:33:11Z | 2026-02789 | 0 | 0 | 09000064b91a649e | |
| FDA-2026-N-0826-0001 | FDA | FDA-2026-N-0826 | Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments— United States (U.S.) 2026–2027 Influenza Vaccine Strain Composition | Notice | Request for Comments | 2026-02-12T05:00:00Z | 2026 | 2 | 2026-02-12T05:00:00Z | 2026-03-12T03:59:59Z | 2026-02-28T10:00:15Z | 2026-02787 | 1 | 0 | 09000064b91a649f |
| FDA-2026-N-0302-0001 | FDA | FDA-2026-N-0302 | Butylated Hydroxyanisole (BHA); Request for Information | Notice | Requests for Information (RFI) | 2026-02-11T05:00:00Z | 2026 | 2 | 2026-02-11T05:00:00Z | 2026-04-14T03:59:59Z | 2026-02-27T10:00:23Z | 2026-02761 | 1 | 0 | 09000064b91a25bf |
| FDA-2023-N-5706-0003 | FDA | FDA-2023-N-5706 | Voluntary Quality Management Maturity Prototype Assessment Protocol Evaluation Program | Notice | Announcement | 2026-02-11T05:00:00Z | 2026 | 2 | 2026-02-11T05:00:00Z | 2026-02-11T19:17:34Z | 2026-02768 | 0 | 0 | 09000064b91a26d1 | |
| FDA-2025-E-0152-0006 | FDA | FDA-2025-E-0152 | Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY | Notice | Determinations | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-08-06T03:59:59Z | 2026-02-06T20:05:43Z | 2026-02388 | 1 | 0 | 09000064b919467e |
| FDA-2026-D-0207-0001 | FDA | FDA-2026-D-0207 | E22 General Considerations for Patient Preference Studies; International Council for Harmonisation; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-02-06T19:33:49Z | 2026-02324 | 0 | 0 | 09000064b9195d41 | |
| FDA-2024-D-2033-0054 | FDA | FDA-2024-D-2033 | Agency Information Collection Activities; Proposed Collection; Comment Request; Expedited Programs for Serious Conditions—Accelerated Approval of Drugs and Biologics | Notice | 60 Day Proposed Information Collection | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-04-08T03:59:59Z | 2026-02-06T19:55:42Z | 2026-02386 | 1 | 0 | 09000064b9195c65 |
| FDA-2024-E-3536-0006 | FDA | FDA-2024-E-3536 | Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV–ICD | Notice | Determinations | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-02-06T20:29:55Z | 2026-02383 | 0 | 0 | 09000064b9195b55 | |
| FDA-2025-E-0153-0006 | FDA | FDA-2025-E-0153 | Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY | Notice | Determinations | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-08-06T03:59:59Z | 2026-02-06T20:06:34Z | 2026-02388 | 1 | 0 | 09000064b919467f |
| FDA-2024-E-3539-0006 | FDA | FDA-2024-E-3539 | Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ | Notice | Determinations | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-08-06T03:59:59Z | 2026-02-14T13:19:52Z | 2026-02387 | 1 | 0 | 09000064b9195b4d |
| FDA-2024-E-3535-0006 | FDA | FDA-2024-E-3535 | Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV–ICD | Notice | Determinations | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-02-06T20:29:21Z | 2026-02383 | 0 | 0 | 09000064b9196229 | |
| FDA-2026-N-0232-0001 | FDA | FDA-2026-N-0232 | Medical Devices; Exemptions From Premarket Notification: Class II Devices; Request for Comments | Notice | Request for Comments | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-04-08T03:59:59Z | 2026-02-26T10:00:18Z | 2026-02377 | 1 | 0 | 09000064b9195af7 |
| FDA-2025-E-1227-0006 | FDA | FDA-2025-E-1227 | Determination of Regulatory Review Period for Purposes of Patent Extension; ALFAPUMP | Notice | Determinations | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-04-08T03:59:59Z | 2026-02-11T02:11:43Z | 2026-02384 | 1 | 0 | 09000064b9195d0d |
| FDA-2025-N-1956-0002 | FDA | FDA-2025-N-1956 | Matthew Teltser: Final Debarment Order | Notice | General Notice | 2026-02-06T05:00:00Z | 2026 | 2 | 2026-02-06T05:00:00Z | 2026-02-06T20:25:04Z | 2026-02349 | 0 | 0 | 09000064b9195b88 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);